Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Market Size of the Neulasta Market In 2029?
In recent times, the neulasta market has seen a substantial rise of XX (HCAGR). This market, worth $XX million in 2024, is projected to increase to a staggering $XX million in 2025, marking a compound annual growth rate (CAGR) of XX%. Factors contributing to this impressive growth during the historical period include the escalating occurrence of chemotherapy-induced neutropenia, a worldwide surge in cancer cases, enhanced understanding of neutropenia risks during cancer therapies, the presence of favorable government funding for biologics, and the early integration of biologics in advanced regions.
What Growth Rate Is Forecasted for the Neulasta Market by 2029?
In the forthcoming years, the neulasta market is projected to witness a XX (FCAGR) surge, amassing a value of $XX million by 2029, with a compound annual growth rate (CAGR) of XX%. The market expansion during the predicted period may largely be due to factors such as the proliferation of biosimilars in burgeoning markets, an escalating demand for affordable cancer-supportive aid, mushrooming healthcare spending globally, an uptick in endorsements for biosimilars by regulatory bodies, and enhanced patient discernment regarding biosimilar substitutes. Prominent trends forecasted for the period include advancements in the creation of prefilled syringes for improved administration, evolution in drug delivery systems like on-body injectors, integration of digital platforms for patient enlightenment, usage of AI for enhancing biologics R&D and optimizing supply chains, and tactical alliances established between biologic and biosimilar organizations.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20159&type=smp
Which Key Companies Are Shaping the Future of the Neulasta Market?
Major companies operating in the neulasta market include Amgen Inc.
Which Factors Are Driving Demand in the Neulasta Industry?
The escalating rate of cancer instances is propelling the expansion of the neulasta market. Cancer, typified by irregular cell growth that can extend to other parts of the body, is on the rise, attributed to factors such as an aging population, unhealthy lifestyles, and environmental influences. Biosimilars of Pegfilgrastim, like neulasta, are essential for patients battling cancer and undergoing chemotherapy. They avert chemotherapy-induced neutropenia by triggering white blood cells production, thereby decreasing the threat of infections. Notably, the Australian Institute of Health and Welfare speculated in August 2024 that by the year 2034, Australia should brace for about 209,000 fresh cancer diagnoses. This will show a marked jump from the projected 169,000 cases in 2024. Furthermore, in 2024, cancer is predicted to cause nearly 30% of all deaths in the nation. Thus, the increasing incidence of cancer will fuel the growth of the neulasta market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=20159&type=smp
How Is the Neulasta Market Segmented by Several Divisions?
The neulasta market covered in this report is segmented –
1) By Indication: Chemotherapy-Induced Neutropenia, Bone Marrow Transplantation, Other Indications
2) By Formulation: Injectable Solution, Pre-Filled Syringes Or Pens
3) By Distribution Channel: Hospitals, Oncology Clinics, Specialty Pharmacies, Home Healthcare Services
4) By End User Patients: Adult Patients, Pediatric Patients
What are the Emerging Market Trends Driving the Growth of the Neulasta Industry?
A significant trend in the neulasta market is the innovation of drug delivery mechanisms such as prefilled autoinjectors, which are giving companies a leg up in the sector. These autoinjectors are self-injection contraptions that come preloaded with medication, specifically intended for straightforward and manageable self-administration by patients. To illustrate, in March 2023, the FDA gave its approval for Coherus Biosciences, a biopharmaceutical firm based in the US, to release a single-dose version of their pegfilgrastim biosimilar, Udenyca (pegfilgrastim-cbqv), used in the treatment and reduction of febrile neutropenia, a frequent side effect of chemotherapy. Through this autoinjector, patients are able to self administer pegfilgrastim the day following chemotherapy, mitigating the risk of febrile neutropenia. The design of the device enables an effortless push-on-skin activation for a swift and thorough delivery of a full dose of pegfilgrastim.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/neulasta-global-market-report
Which Regions Are Driving Growth in the Neulasta Market?
North America was the largest region in the neulasta market in 2024. The regions covered in the neulasta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20159
This Report Delivers Insight On:
1. How big is the neulasta market, and how is it changing globally?
2. Who are the major companies in the neulasta market, and how are they performing?
3. What are the key opportunities and risks in the neulasta market right now?
4. Which products or customer segments are growing the most in the neulasta market?
5. What factors are helping or slowing down the growth of the neulasta market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model